You just read:

Soligenix Announces Positive Recommendation by Data Review Committee on its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients

News provided by

Soligenix, Inc.

Mar 03, 2015, 07:00 ET